DELTICOM-AG/YOURTYRES
13.10.2016 12:09:02 CEST | Business Wire | Press release
They’re technological milestones with cult status and are now in high demand: modern classics. Lovers of the Saab 900, the Ford Granada, the Audi 80 and co. place great importance on maintaining their vehicles as true to the original condition as possible. This applies in particular to parts that are prone to wear, such as tyres. Sooner or later they have to be replaced, as even with low mileage they age, harden and eventually crack. “An opportunity for tyre dealers and workshops: even businesses that don’t specialise in classic cars or modern classics can capture the cult vehicle fan target group”, explains Andreas Faulstich, Head of B2B at Delticom, Europe’s largest online tyre retailer, and parent company to the online shop for dealers,Yourtyres.co.uk . “It’s impossible for one retailer to stock absolutely every model and dimension of tyre for historical cars. This is where Yourtyres.co.uk’s retail partnership model comes into play, effectively binding online and offline trade together in a way that is profitable for both sides.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161013005602/en/
Yourtyres.co.uk offers a wide range of historical tyre models and dimensions that today are produced to meet current standards by many well-known manufacturers, for example the “Sprint Classic” by Vredestein, or Maxxi’s “MA 1”. Exclusive to Delticom’s dealer shop, commercial customers can get their hands on the “Retro Classic 001” by Retro, a classic car tyre offering a great price-performance ratio, produced in-house by Nankang and also available as a whitewall tyre.
Searching for the perfect tyre is quick and easy. Prospective buyers can search by tyre dimension or vehicle model. Thanks to its own stock holding and consequent high availability, commercial customers also benefit from one of Yourtyres.co.uk ’s greatest strengths: its flexibility. Delivery times are short, and shipping is free from the very first tyre. If you need advice, you can contact Delticom’s experienced B2B Services team via email or by phone. Consultants are available from 7am to 10pm Monday to Friday, above and beyond normal business hours. Favourable purchase prices also allow partners of Delticom B2B and Yourtyres.co.uk to achieve attractive margins.
“We want to enable dealers and workshops to increase their end-user reach. Distributing historical tyre models is a great way to do this. Another way to increase your reach even further is to register as a fitting partner for Yourtyres.co.uk free of charge. This provides businesses with the potential to benefit from each and every online purchase in one of our end-customer shops”, expands Faulstich. “In addition to tyre fitting, further services can be connected to workshops or retail outlets, enabling an expansion of the business.”
About Yourtyres.co.uk
Yourtyres.co.uk de is the exclusive online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years’ expertise in the online tyre business, the Yourtyres.co.uk specialist B2B team offers its clients a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail clients benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses, as well as a simple registration process with no hidden costs - from the very first tyre.
Online shop for dealers and workshops in the UK: www.yourtyres.co.uk and 24 further countries.
Information about the company : www.delti.com
Tyre tests : www.tyretest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005602/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom